RecruitingPHASE2, PHASE3NCT07555392
A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.
Studying Chikungunya
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bharat Biotech International Limited
- Intervention
- BBV87 Chikungunya vaccine(biological)
- Enrollment
- 1000 target
- Eligibility
- 12-65 years · All sexes
- Timeline
- 2026 – 2027
Study locations (10)
- All India Institute of Medical Sciences, Guwahati, Assam, India
- All India Institute of Medical Sciences, Patna, Bihar, India
- All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
- Redkar Hospital and Research Centre, Mumbai, Goa, India
- PGIMS, Rohtak, Haryana, India
- IMS & SUM Hospital bhubaneshwar Institute of Medical Sciences & SUM Hospital, Bhubaneswar, Odisha, India
- Jawahar Lal Nehru medical College, Ajmer, Rajasthan, India
- Sardar Patel Medical College, Bikaner, Rajasthan, India
- Guru Teg Bahadur Hospital, Delhi, The National Capital Territory (nct) of Delhi, India
- AIIMS Rishikesh Department of Community Medicine, Rishikesh, Uttarakhand, India
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07555392 on ClinicalTrials.govOther trials for Chikungunya
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07347002Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ENROLLING BY INVITATIONNCT07254702Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ACTIVE NOT RECRUITINGNCT07163845Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ENROLLING BY INVITATIONNCT07520279Xpert® Tropical Fever Test on GeneXpert® Edge X SystemCepheid
- ACTIVE NOT RECRUITINGNCT06651372The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return TravelersUniversity Hospital, Strasbourg, France
- RECRUITINGNCT07120724Real-World Study on Chinese Medicine for Treating Chikungunya FeverGuangzhou University of Traditional Chinese Medicine
- RECRUITINGPHASE3NCT07003984A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.Bavarian Nordic
- RECRUITINGPHASE4NCT06928753Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La RéunionCentre Hospitalier Universitaire de la Réunion